Genmab — Juli 2023
-
fantastisk nyhed omkring Kesimpta. Har i husstanden en person med diagnosen SPMS (sekundær progressiv) . I dette tilfælde, er løbet desværre kørt, idet der samtidig er konstateret en kræftsygdom i sen stadie. Men en kæmpe nyhed for alle, der har diagnosen i tidligt stadie.
-
@Solsen. Tror du misforstår. Med baggrund i kræftsygdommen, bliver der ikke tilbudt Kesimpta mod skelrosen.
-
EDITED TRANSCRIPT
JNJ.N - Johnson & Johnson at Goldman Sachs Healthcare Conference
EVENT DATE/TIME: JUNE 13, 2023 https://johnsonandjohnson.gcs-web.com/static-files/721c4f73-1151-489f-8bd2-82e81c872642 -
Bundproppen Genmab! Dårligste C-25 aktie med et afkast på -12,72% i 1. halvår https://borsen.dk/nyheder/investor/efter-seks-maaneders-handel-her-er-top-aktierne-og-aktierne-i-modvind?b_source=borsen&b_medium=row_2&b_campaign=news_2
-
Epco/Could This New Drug Be a
Blockbuster for These 2 Pharma Collaborators? https://www.proinvestor.com/investornyt/1009032/could-this-new-drug-be-a-blockbuster-for-these-2-pharma-collaborators -
Forward P/E 37.78: https://www.nasdaq.com/market-activity/stocks/gmab
-
Innovent Biologics : China Approves
FUCASO NDA For Relapsed/Refractory Multiple Myeloma Treatment https://www.proinvestor.com/investornyt/1009107/innovent-biologics-china-approves-fucaso-nda-for-relapsed-refractory-multiple-myeloma-treatment -
Shortpositioner på danske aktier https://www.proinvestor.com/boards/113673
-
Godmorgen

-
Shortpositioner på danske aktier https://www.proinvestor.com/boards/113702
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind